CADL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CA

Mkt Cap

$625.1M

Volume

1.34M

Next Earnings

November 12th

Loading chart

CA

CADLCandel Therapeutics, Inc. Common Stock

CADL

Pay with—

Available Balance0.00

CA

Mkt Cap

$626.7M

Volume

1.34M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Candel Therapeutics to Present at the SITC 2026 Annual MeetingCandel Therapeutics announced that it will present data from its aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from its phase 1b trial of linoserpaturev in recurrent glioblastoma at the Society for Immunotherapy of Cancer's 41st Annual Meeting in November 2026. The presentations will showcase multi-omics analyses revealing immune activation and improved survival outcomes.GlobeNewswire Inc. · Oct 2, 2026

4 Prostate Cancer Drug Stocks to Watch During Awareness MonthAs prostate cancer incidence rises with advanced-stage diagnoses increasing, four pharmaceutical companies are advancing treatments. Pfizer and Novartis, with established prostate cancer franchises, await FDA decisions on label expansions for Talzenna/Xtandi and Pluvicto respectively. Candel and Janux, earlier-stage developers, are preparing regulatory filings and advancing clinical programs in this growing market.Zacks Investment Research · Sep 15, 2026

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED)U.S. stock futures rose on Friday ahead of Q4 GDP data and PCE inflation gauge releases. Markets are pricing in a 94% likelihood of unchanged Fed rates in March. Notable movers include Copart missing earnings expectations, Comfort Systems raising dividends, Grail plunging 47% on weak earnings, Candel Therapeutics declining on stock offering announcement, and Dropbox falling despite beating earnings. Wells Fargo strategist recommends leaning into growth-sensitive sectors like Financials and Industrials rather than defensive positioning.Benzinga · Feb 20, 2026

Candel Therapeutics Announces Pricing of Public OfferingCandel Therapeutics announced a public offering of 18.3 million shares at $5.45 per share, raising $100 million in gross proceeds. The company plans to use the funds for launch readiness and commercialization of aglatimagene besadenovec for localized prostate cancer, ongoing phase 3 trials in non-small cell lung cancer, and general corporate purposes. The offering is expected to close on February 23, 2026.GlobeNewswire Inc. · Feb 20, 2026

Candel Therapeutics Announces Proposed $100 Million Public OfferingCandel Therapeutics (NASDAQ: CADL) announced a proposed $100 million public offering of common stock, with an additional $15 million option for underwriters. The company plans to use proceeds for launch readiness, commercialization activities, and development of aglatimagene for prostate cancer and non-small cell lung cancer, along with general corporate purposes. Citigroup, Cantor, and Stifel are acting as joint bookrunning managers.Benzinga · Feb 19, 2026

Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031The global oncolytic virotherapy market is projected to grow from USD 49.73 million in 2025 to USD 153.31 million by 2031, with a CAGR of 20.64%. Growth is driven by rising cancer incidence, advances in genetic engineering, and synergistic combination therapies with checkpoint inhibitors. However, host immune system challenges and premature viral clearance remain significant obstacles to market expansion.GlobeNewswire Inc. · Jan 23, 2026

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid TumorsCandel Therapeutics presented three key research presentations at SITC 2025, highlighting advances in immunotherapy for solid tumors using multi-omics analysis and artificial intelligence, including promising phase 3 clinical trial results for CAN-2409 in prostate cancer and preclinical data from their enLIGHTEN™ Discovery Platform.GlobeNewswire Inc. · Nov 4, 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma PatientsCandel Therapeutics published positive phase 1b clinical trial data on the combination of CAN-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma patients, demonstrating a promising safety profile and potential survival benefit.GlobeNewswire Inc. · Apr 1, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory BoardCandel Therapeutics, a clinical-stage biopharmaceutical company, has appointed Elizabeth M. Jaffee, M.D., a renowned expert in pancreatic cancer and immunology, to its Research Advisory Board. This appointment aligns with Candel's focus on developing multimodal biological immunotherapies for cancer treatment, particularly in borderline resectable pancreatic cancer.GlobeNewswire Inc. · Mar 18, 2025

Candel Therapeutics Announces $80 Million Proposed Public OfferingCandel Therapeutics, a clinical-stage biopharmaceutical company, announced the launch of an $80 million public offering of its common stock and pre-funded warrants. The company plans to use the proceeds to continue the development of its product candidates, including preparing the submission of a Biologics License Application for CAN-2409 in prostate cancer.GlobeNewswire Inc. · Dec 12, 2024

to start trading

CA

CADLCandel Therapeutics, Inc. Common Stock

CADL

Pay with—

Available Balance0.00

Your PositionYou don't own any CADL yet.

Related Tickers

Earnings